GSK

​GSK is a world’s leading vaccine company, with a portfolio that helps protect people at every stage of life    

In 2022, the company invested £5.5 billion in R&D, further growing a budget that has built a pipeline of 69 vaccines and medicines, many with potential to be first or best-in-class treatments for patients. As GSK’s eight consecutive years at the top of the Access to Medicine Index (ATMI) show, diseases affecting the developing world are a particular focus. Our unrivalled portfolio targets infectious diseases at every stage of life helping protect people from meningitis, shingles, flu, polio, measles and many more. 

Uniting science, talent and technologies to get ahead of disease  

We prevent and treat disease with vaccines, specialty and general medicines and we are a world leader in infectious diseases. We focus on the science of the immune system, human genetics and advanced technologies, investing in 4 core therapeutic areas and future opportunities to impact health at scale. GSK, with more than 180 scientific collaborations in 2021 continues to scout for partners on projects spanning discovery to late-phase development, to accelerate vaccine development and strengthen supply performance. Ultimately, uniting forces through strategic partnerships will help deliver greater impact for patients around the world.